MaxCyte Inc.
08/11/2022 | Press release | Archived content
Filing of Form 10-Q for Second Quarter
MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022
ROCKVILLE, MD, August 11, 2022- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), aleading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization,today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended June 30, 2022.
A copy of the Form 10-Q is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/.
MaxCyte Contacts:
|
US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400 |
|
US Media Relations Seismic Valerie Enes Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+1 408-497-8568 +44 (0)20 7886 2500 |
|
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700 |